A randomized, double-blind, placebo-controlled trial of intravenous alpha-1 antitrypsin for ARDS secondary to COVID-19

BACKGROUND: Patients with severe coronavirus disease 2019 (COVID-19) develop a febrile pro-inflammatory cytokinemia with accelerated progression to acute respiratory distress syndrome (ARDS). Here we report the results of a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of...

Descripción completa

Detalles Bibliográficos
Autores principales: McElvaney, Oliver J., McEvoy, Natalie L., Boland, Fiona, McElvaney, Oisín F., Hogan, Grace, Donnelly, Karen, Friel, Oisín, Browne, Emmet, Fraughen, Daniel D., Murphy, Mark P., Clarke, Jennifer, Choileáin, Orna Ní, O’Connor, Eoin, McGuinness, Rory, Boylan, Maria, Kelly, Alan, Hayden, John C., Collins, Ann M., Cullen, Ailbhe, Hyland, Deirdre, Carroll, Tomás P., Geoghegan, Pierce, Laffey, John G., Hennessy, Martina, Martin-Loeches, Ignacio, McElvaney, Noel G., Curley, Gerard F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2022
Materias:
Clinical Advances
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913266/
https://www.ncbi.nlm.nih.gov/pubmed/35291694
http://dx.doi.org/10.1016/j.medj.2022.03.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913266/
https://www.ncbi.nlm.nih.gov/pubmed/35291694
http://dx.doi.org/10.1016/j.medj.2022.03.001

Ejemplares similares